Bayer's Weinand On Broadening Value-Based Pricing Views

 
• By Lucie Ellis-Taitt

Bayer's pharma head Dieter Weinand talks about his biggest issues with current value-based pricing assessments for new drugs and how companion diagnostics will pave the way to easier pricing of oncology therapies.

IV1703_Medicine Gets Personal_1200x675
Weinand says industry is on the cusp of a scientific revolution • Source: Shutterstock

More from Drug Pricing

More from Scrip